Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
Cerqueira-Silva T, Andrews JR, Boaventura VS, Ranzani OT, de Araújo Oliveira V, Paixão ES, Júnior JB, Machado TM, Hitchings MDT, Dorion M, Lind ML, Penna GO, Cummings DAT, Dean NE, Werneck GL, Pearce N, Barreto ML, Ko AI, Croda J, Barral-Netto M. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. The Lancet Infectious Diseases 2022, 22: 791-801. PMID: 35366959, PMCID: PMC8971277, DOI: 10.1016/s1473-3099(22)00140-2.Peer-Reviewed Original ResearchConceptsPrevious SARS-CoV-2 infectionSARS-CoV-2 infectionChAdOx1 nCoV-19Negative RT-PCR testRT-PCR testVaccine series completionCase-control studySymptomatic infectionCOVID-19 vaccineNCoV-19Symptomatic illnessVaccine seriesSecond doseSevere outcomesSeries completionTwo-dose vaccine seriesPositive RT-PCR testInitial SARS-CoV-2 infectionMultivariable conditional logistic regressionCOVID-19Effectiveness of CoronaVacFull vaccine seriesMore daysOdds of hospitalisationSymptomatic COVID-19